Digna & Flamel to Develop Multiple Candidates

Under terms of the deal Flamel will primarily be responsible for formulation and process development, with Digna shouldering preclinical and clinical development activities.

French firm Flamel Technologies and Spanish firm Digna Biotech have announced that the two companies will jointly develop a number of the latter’s candidates using Flamel’s Medusa? and Micropump? drug delivery technologies.

Under terms of the deal Flamel will primarily be responsible for formulation and process development, with Digna shouldering preclinical and clinical development activities.

Three initial Digna candidates have initially been selected for co-development.  P144 (disitertide) is a TGF-beta1 inhibitor that has already been evaluated in topical form in a Phase II trial as a treatment for systemic sclerosis or scleroderma. Preclinical studies in a model of organ fibrosis and macular degeneration have also been carried out. Through the collabo